ERBB2 and cancer: In our previous study, we demonstrated that the anti-HER2 affibody ZHER2:2891, originally designed by Feldwisch et al. (2010) efficiently delivers a highly cytotoxic antimitotic agent, auristatin E, to HER2-positive cancer cells [19].